7993 results
Cited 9 times since 2017 (1.1 per year)
source: EuropePMC
Circulation. Cardiovascular genetics,
Volume 10, Issue 2, 1 1 2017, Pages e001664
Additional Candidate Genes for Human Atherosclerotic Disease Identified Through Annotation Based on Chromatin Organization.
Haitjema S, Meddens CA, van der Laan SW, Kofink D, Harakalova M, Tragante V, Foroughi Asl H, van Setten J, Brandt MM, Bis JC, O'Donnell C, Cheng C, Hoefer IE, Waltenberger J, Biessen E, Jukema JW, Doevendans PA, Nieuwenhuis EE, Erdmann J, Björkegren JL, Pasterkamp G, Asselbergs FW, den Ruijter HM, Mokry M
Background: As genome-wide association efforts, such as CARDIoGRAM and METASTROKE, are ongoing to reveal susceptibility loci for their underlying disease-atherosclerotic disease-identification of candidate genes explaining the associations of these loci has proven the main challenge. Many disease susceptibility loci colocalize with DNA regulatory elements, which influence gene expression through chromatin interactions. Therefore, the target genes of these regulatory elements can be considered ca...
Abstract
Cited 98 times since 2017 (12.3 per year)
source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation,
Volume 25, Issue 4, 1 1 2017, Pages 231-242
Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment.
Bergheanu SC, Bodde MC, Jukema JW
Recent years have brought a significant amount of new results in the field of atherosclerosis. A better understanding of the role of different lipoprotein particles in the formation of atherosclerotic plaques is now possible. Recent cardiovascular clinical trials have also shed more light upon the efficacy and safety of novel compounds targeting the main pathways of atherosclerosis and its cardiovascular complications.In this review, we first provide a background consisting of the current unders...
Abstract
Cited 5 times since 2017 (0.6 per year)
source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Volume 19, Issue 4, 1 1 2017, Pages 560-567
Limited left atrial surgical ablation effectively treats atrial fibrillation but decreases left atrial function.
Compier MG, Tops LF, Braun J, Zeppenfeld K, Klautz RJ, Schalij MJ, Trines SA
Aims: Limited left atrial (LA) surgical ablation with bipolar radiofrequency is considered to be an effective procedure for treatment of atrial fibrillation (AF). We studied whether limited LA surgical ablation concomitant to cardiac surgery is able to maintain LA function. Methods and results: Thirty-six consecutive patients (age 66 ± 12 years, 53% male, 78% persistent AF) scheduled for valve surgery and/or coronary revascularization and concomitant LA surgical ablation were included. Epicardia...
Abstract
Cited 15 times since 2017 (1.9 per year)
source: EuropePMC
Oncotarget,
Volume 8, Issue 17, 1 1 2017, Pages 28650-28659
Expression of HIF-1α in medullary thyroid cancer identifies a subgroup with poor prognosis.
Lodewijk L, van Diest P, van der Groep P, Ter Hoeve N, Schepers A, Morreau J, Bonenkamp J, van Engen-van Grunsven A, Kruijff S, van Hemel B, Links T, Nieveen van Dijkum E, van Eeden S, Valk G, Borel Rinkes I, Vriens M
Background: Medullary thyroid cancer (MTC) comprises only 4% of all thyroid cancers and originates from the parafollicular C-cells. HIF-1α expression has been implied as an indicator of worse prognosis in various solid tumors. However, whether expression of HIF-1α is a prognosticator in MTC remained unclear. Our aim was to evaluate the prognostic value of HIF-1α in patients with MTC. Methods: All patients with MTC who were operated on between 1988 and 2014 in five tertiary referral centers in Th...
Abstract
Cited 5 times since 2017 (0.6 per year)
source: EuropePMC
Pharmaceutical research,
Volume 34, Issue 6, 31 5 2017, Pages 1309-1319
Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype.
Fattah S, Shinde AB, Matic M, Baes M, van Schaik RHN, Allegaert K, Parmentier C, Richert L, Augustijns P, Annaert P
Purpose: OCT1/3 (Organic Cation Transporter-1 and -3; SLC22A1/3) are transmembrane proteins localized at the basolateral membrane of hepatocytes. They mediate the uptake of cationic endogenous compounds and/or xenobiotics. The present study was set up to verify whether the previously observed variability in OCT activity in hepatocytes may be explained by inter-individual differences in OCT1/3 mRNA levels or OCT1 genotype. Methods: Twenty-seven batches of cryopreserved human hepatocytes (male and...
Abstract
Cited 22 times since 2017 (2.8 per year)
source: EuropePMC
Proceedings of the National Academy of Sciences of the United States of America,
Volume 114, Issue 15, 27 4 2017, Pages E3022-E3031
High-throughput identification of small molecules that affect human embryonic vascular development.
Vazão H, Rosa S, Barata T, Costa R, Pitrez PR, Honório I, de Vries MR, Papatsenko D, Benedito R, Saris D, Khademhosseini A, Quax PH, Pereira CF, Mercader N, Fernandes H, Ferreira L
Birth defects, which are in part caused by exposure to environmental chemicals and pharmaceutical drugs, affect 1 in every 33 babies born in the United States each year. The current standard to screen drugs that affect embryonic development is based on prenatal animal testing; however, this approach yields low-throughput and limited mechanistic information regarding the biological pathways and potential adverse consequences in humans. To develop a screening platform for molecules that affect hum...
Abstract
Cited 30 times since 2017 (3.8 per year)
source: EuropePMC
BJU international,
Volume 120, Issue 1, 24 4 2017, Pages 12-24
Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer.
Veskimäe E, Neuzillet Y, Rouanne M, MacLennan S, Lam TBL, Yuan Y, Compérat E, Cowan NC, Gakis G, van der Heijden AG, Ribal MJ, Witjes JA, Lebrét T
Context: Pelvic organ-preserving radical cystectomy (POPRC) for women may improve postoperative sexual and urinary functions without compromising the oncological outcome compared with standard radical cystectomy (RC). Objective: To determine the effect of POPRC on sexual, oncological and urinary outcomes compared with RC in women who undergo standard curative surgery and orthotopic neobladder substitution for bladder cancer. Evidence acquisition: Medline, Embase, Cochrane controlled trials datab...
Abstract
Heart rhythm,
Volume 14, Issue 7, 23 4 2017, Pages 1051-1052
The right timing for the left lead: Now or later?
Yilmaz D, van Erven L, Borleffs CJW, Thijssen J
Abstract
Cited 2 times since 2017 (0.3 per year)
source: EuropePMC
Minerva cardioangiologica,
Volume 65, Issue 5, 23 4 2017, Pages 516-530
Multimodality imaging to plan and guide transcatheter tricuspid valve interventions.
Prihadi EA, Delgado V, Bax JJ
Tricuspid regurgitation (TR) is a highly prevalent valvular heart disease. The natural history of untreated significant TR portends an unfavorable outcome, but only a minority of patients is currently referred for surgical treatment. Organic TR (caused by primary abnormality of the leaflets) is relatively infrequent whereas secondary or functional TR (caused by dilatation of the tricuspid annulus, right ventricle [RV] and right atrium) is the predominant mechanism. The success of transcatheter t...
Abstract
Cited 13 times since 2017 (1.6 per year)
source: EuropePMC
BMC evolutionary biology,
Volume 17, Issue 1, 23 4 2017, Pages 89
Exploring the evolutionary origin of floral organs of Erycina pusilla, an emerging orchid model system.
Dirks-Mulder A, Butôt R, van Schaik P, Wijnands JW, van den Berg R, Krol L, Doebar S, van Kooperen K, de Boer H, Kramer EM, Smets EF, Vos RA, Vrijdaghs A, Gravendeel B
Background: Thousands of flowering plant species attract pollinators without offering rewards, but the evolution of this deceit is poorly understood. Rewardless flowers of the orchid Erycina pusilla have an enlarged median sepal and incised median petal ('lip') to attract oil-collecting bees. These bees also forage on similar looking but rewarding Malpighiaceae flowers that have five unequally sized petals and gland-carrying sepals. The lip of E. pusilla has a 'callus' that,...
Abstract
Cited 6 times since 2017 (0.8 per year)
source: EuropePMC
Pacing and clinical electrophysiology : PACE,
Volume 40, Issue 5, 23 4 2017, Pages 504-513
Effects of Spinal Cord Stimulation on Cardiac Sympathetic Nerve Activity in Patients with Heart Failure.
Naar J, Jaye D, Linde C, Neužil P, Doškář P, Málek F, Braunschweig F, Lund LH, Mortensen L, Linderoth B, Lind G, Bone D, Scholte AJ, Kueffer F, Koehler J, Shahgaldi K, Lang O, Ståhlberg M
Background: Spinal cord stimulation (SCS) reduces sympathetic activity in animal models of heart failure with reduced ejection fraction (HF) but limited data exist of SCS in patients with HF. The aim of the present study was to test the primary hypothesis that SCS reduces cardiac sympathetic nerve activity in HF patients. Secondary hypotheses were that SCS improves left ventricular function and dimension, exercise capacity, and clinical variables relevant to HF. Methods: HF patients with a SCS d...
Abstract
Cited 5 times since 2017 (0.6 per year)
source: EuropePMC
Environmental management,
Volume 62, Issue 1, 21 3 2017, Pages 170-181
Participatory Planning, Monitoring and Evaluation of Multi-Stakeholder Platforms in Integrated Landscape Initiatives.
Kusters K, Buck L, de Graaf M, Minang P, van Oosten C, Zagt R
Integrated landscape initiatives typically aim to strengthen landscape governance by developing and facilitating multi-stakeholder platforms. These are institutional coordination mechanisms that enable discussions, negotiations, and joint planning between stakeholders from various sectors in a given landscape. Multi-stakeholder platforms tend to involve complex processes with diverse actors, whose objectives and focus may be subjected to periodic re-evaluation, revision or reform. In this articl...
Abstract
Cited 1 times since 2017 (0.1 per year)
source: EuropePMC
BMJ open,
Volume 7, Issue 3, 20 3 2017, Pages e014360
Design and reliability of a specific instrument to evaluate patient safety for patients with acute myocardial infarction treated in a predefined care track: a retrospective patient record review study in a single tertiary hospital in the Netherlands.
Eindhoven DC, Borleffs CJ, Dietz MF, Schalij MJ, Brouwers C, de Bruijne MC
Objective: Numerous studies have shown that a substantial number of patients suffer from adverse events (AEs) as a result of hospital care. However, specific data on AEs in acute cardiac care are scarce. The current manuscript describes the development and validation of a specific instrument to evaluate patient safety of a predefined care track for patients with acute myocardial infarction (AMI). Design: Retrospective patient record review study. Setting and participants: A total of 879 hospital...
Abstract
Cited 5 times since 2017 (0.6 per year)
source: EuropePMC
Lancet (London, England),
Volume 389, Issue 10087, 19 3 2017, Pages 2352-2354
Bioprosthetic surgical and transcatheter heart valve thrombosis.
Bax JJ, Stone GW
Abstract
Cited 158 times since 2017 (19.7 per year)
source: EuropePMC
Journal of the American College of Cardiology,
Volume 69, Issue 21, 18 3 2017, Pages 2579-2589
Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis.
Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, Barbanti M, Sharma R, Perlman GY, Khalique OK, Holy EW, Saraf S, Deuschl F, Fujita B, Ruile P, Neumann FJ, Pache G, Takahashi M, Kaneko H, Schmidt T, Ohno Y, Schofer N, Kong WKF, Tay E, Sugiyama D, Kawamori H, Maeno Y, Abramowitz Y, Chakravarty T, Nakamura M, Kuwata S, Yong G, Kao HL, Lee M, Kim HS, Modine T, Wong SC, Bedgoni F, Testa L, Teiger E, Butter C, Ensminger SM, Schaefer U, Dvir D, Blanke P, Leipsic J, Nietlispach F, Abdel-Wahab M, Chevalier B, Tamburino C, Hildick-Smith D, Whisenant BK, Park SJ, Colombo A, Latib A, Kodali SK, Bax JJ, Søndergaard L, Webb JG, Lefèvre T, Leon MB, Makkar R
Background: Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with bicuspid aortic valve stenosis (AS). Objectives: This study sought to compare the procedural and clinical outcomes in patients with bicuspid versus tricuspid AS from the Bicuspid AS TAVR multicenter registry. Methods: Outcomes of 561 patients with bicuspid AS and 4,546 patients with tricuspid AS were compared after propensity score matching, assembling 546 pairs of patients with similar bas...
Abstract
Cited 312 times since 2017 (38.9 per year)
source: EuropePMC
The New England journal of medicine,
Volume 376, Issue 16, 17 3 2017, Pages 1527-1539
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC, SPIRE Cardiovascular Outcome Investigators
Background: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. Methods: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) sub...
Abstract
Cited 154 times since 2017 (19.2 per year)
source: EuropePMC
The New England journal of medicine,
Volume 376, Issue 16, 17 3 2017, Pages 1517-1526
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C, SPIRE Investigators
Background: Bococizumab, a humanized monoclonal antibody targeting proprotein convertase subtilisin-kexin type 9 (PCSK9), reduces levels of low-density lipoprotein (LDL) cholesterol. However, the variability and durability of this effect are uncertain. Methods: We conducted six parallel, multinational lipid-lowering trials enrolling 4300 patients with hyperlipidemia who were randomly assigned to receive 150 mg of bococizumab or placebo subcutaneously every 2 weeks and who were followed for up to...
Abstract
Cited 2256 times since 2017 (281.6 per year)
source: EuropePMC
The New England journal of medicine,
Volume 376, Issue 18, 17 3 2017, Pages 1713-1722
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators
Background: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. Methods: We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving s...
Abstract
Cited 5 times since 2017 (0.6 per year)
source: EuropePMC
Open heart,
Volume 4, Issue 1, 15 3 2017, Pages e000541
Prognosis of complete versus incomplete revascularisation of patients with STEMI with multivessel coronary artery disease: an observational study.
Dimitriu-Leen AC, Hermans MP, Veltman CE, van der Hoeven BL, van Rosendael AR, van Zwet EW, Schalij MJ, Delgado V, Bax JJ, Scholte AJ
Objective: The best strategy in patients with acute ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease (CAD) regarding completeness of revascularisation of the non-culprit lesion(s) is still unclear. To establish which strategy should be followed, survival rates over a longer period should be evaluated. The aim of this study was to investigate whether complete revascularisation, compared with incomplete revascularisation, is associated with reduced short-...
Abstract
Cited 11 times since 2017 (1.4 per year)
source: EuropePMC
Molecular therapy. Nucleic acids,
Volume 7, 14 2 2017, Pages 61-70
Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494.
Welten SMJ, de Vries MR, Peters EAB, Agrawal S, Quax PHA, Nossent AY
Improving the efficacy of neovascularization is a promising strategy to restore perfusion of ischemic tissues in patients with peripheral arterial disease. The 14q32 microRNA cluster is highly involved in neovascularization. The Mef2a transcription factor has been shown to induce transcription of the microRNAs within this cluster. We inhibited expression of Mef2a using gene-silencing oligonucleotides (GSOs) in an in vivo hind limb ischemia model. Treatment with GSO-Mef2a clearly improved blood f...
Abstract
